UK markets closed
NIKKEI 225
39,667.07 +493.92 (+1.26%) HANG SENG
18,089.93 +17.03 (+0.09%) CRUDE OIL
80.78 -0.05 (-0.06%) GOLD FUTURES
2,309.00 -21.80 (-0.94%) DOW
39,141.47 +29.31 (+0.07%) Bitcoin GBP
48,160.25 -931.11 (-1.90%)
ITCI Aug 2024 60.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:16AM EDT. Market open.
| Previous close | 16.19 |
| Open | 16.19 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 60.00 |
| Expiry date | 2024-08-16 |
| Day's range | 16.19 - 16.19 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksIntra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
Investor's Business DailyIntra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
The Relative Strength (RS) Rating for Intra-Cellular Therapies stock entered a new percentile Thursday, with a rise from 75 to 87. This unique rating tracks technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the last 52 weeks matches up against the rest of the market.
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
© 2024 Yahoo. All rights reserved.